.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Federal Trade Commission
Mallinckrodt
UBS
Johnson and Johnson
Boehringer Ingelheim
McKesson
QuintilesIMS
Citi

Generated: June 26, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,612,102

« Back to Dashboard

Which drugs does patent 7,612,102 protect, and when does it expire?


Patent 7,612,102 protects CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, and CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, and is included in one NDA. There has been one Paragraph IV challenge on Cardene in 0.86% Sodium Chloride in plastic container.

This patent has twenty-three patent family members in eleven countries.

Summary for Patent: 7,612,102

Title:Pre-mixed, ready-to-use pharmaceutical compositions
Abstract:Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.
Inventor(s): Duncan; Michelle Renee (Glenview, IL), Gupta; Supriya (Sunnyvale, CA), Haas; David Hartley (Fremont, CA), Stephens; Norma V. (Skokie, IL), Zamiri; Camellia (Fremont, CA)
Assignee: EKR Therapeutics, Inc. (
Application Number:11/788,076
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Chiesi Usa Inc
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER
nicardipine hydrochloride
INJECTABLE;INTRAVENOUS019734-004Nov 7, 2008RXYesYes7,612,102► SubscribeY
Chiesi Usa Inc
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER
nicardipine hydrochloride
INJECTABLE;INTRAVENOUS019734-003Jul 31, 2008RXYesYes7,612,102► SubscribeY
Chiesi Usa Inc
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER
nicardipine hydrochloride
INJECTABLE;INTRAVENOUS019734-002Jul 31, 2008RXYesYes7,612,102► SubscribeY
Chiesi Usa Inc
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER
nicardipine hydrochloride
INJECTABLE;INTRAVENOUS019734-005Nov 7, 2008RXYesYes7,612,102► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,612,102

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,364,564Pre-mixed, ready-to-use pharmaceutical compositions► Subscribe
9,549,994Compositions of nicardipine and sulfoalkylated .beta.-cyclodextrin► Subscribe
7,659,290Methods of preparing pre-mixed, ready-to-use pharmaceutical compositions► Subscribe
8,455,524Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions► Subscribe
9,370,586Methods of preparing pre-mixed, ready-to-use pharmaceutical compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,612,102

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand572226► Subscribe
New Zealand572225► Subscribe
Mexico2008013407► Subscribe
Mexico2008013405► Subscribe
South Korea20090040258► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Julphar
Fuji
McKesson
Daiichi Sankyo
Moodys
Cipla
Express Scripts
Argus Health
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot